BIOPORNasdaq CopenhagenDiagnostics & ResearchIFRS · DKK

BIOPORTO A/S

BIOPORTO A/S is a Danish in vitro diagnostics company focused on kidney biomarker tests for clinical decision-making. Its core business is the development and commercialization of NGAL-based assays used to aid the risk assessment and diagnosis of acute kidney injury, sold under regulatory clearances and registrations in multiple markets.

Kysy yhtiöstä
Liikevaihto40,3milj. DKK
+11,2 %v/v
Liikevoitto (EBIT)−86,1milj. DKK
−14,1 %v/v
EBIT-marginaali−213,7%
−5,5 %-yks.v/v
Nettotulos−82,1milj. DKK
−20,3 %v/v
Vapaa kassavirta−77,1milj. DKK
+8,2 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−100−50050milj. DKK2020: 23 milj. DKK2020: EBIT −64 milj. DKK20202021: 24 milj. DKK2021: EBIT −65 milj. DKK20212022: 29 milj. DKK2022: EBIT −82 milj. DKK20222023: 31 milj. DKK2023: EBIT −61 milj. DKK20232024: 36 milj. DKK2024: EBIT −75 milj. DKK20242025: 40 milj. DKK2025: EBIT −86 milj. DKK202540−86
LiikevaihtoLiikevoitto (EBIT)
Kysy Clarifolta: BIOPORTO A/S

Liiketoiminta

Osuus liikevaihdosta
NGAL diagnostic tests80 %

Commercial assays that measure NGAL to support early detection and risk assessment of acute kidney injury.

Other biomarker products10 %

Adjacent kidney biomarker products and related diagnostic offerings beyond the core NGAL line.

Research-use and assay development10 %

Development-stage biomarker work and related research-use products and services.

Asiakkaat

BioPorto sells into hospitals, clinical laboratories, and healthcare providers that need earlier insight into kidney injury risk. Its products are used by clinicians managing patients where rapid AKI identification can affect treatment decisions and outcomes. The company also serves distribution and diagnostic channel partners that help commercialize regulated IVD products across geographies.

Hospitals and acute care providers

Buy NGAL tests for patients at risk of acute kidney injury to support faster clinical decisions.

Clinical laboratories

Use the assays in routine or specialized testing workflows where kidney biomarkers are needed.

Healthcare systems and physicians

Adopt the tests to improve patient management, diagnosis timing, and care pathways.

Diagnostic distributors

Purchase and resell regulated diagnostic products into local healthcare markets.

Research and development users

Use research-use antibodies and biomarker tools for assay development and evaluation.

Strategia

BioPorto's stated direction is to focus on its core NGAL platform and the biomarker tests most closely tied to acute kidney injury care. The business strategy centers on expanding the clinical footprint of its regulated diagnostics, while using assay-development expertise to build a pipeline of kidney biomarker products. This focus matters because a narrower product strategy can strengthen commercialization, regulatory execution, and clinical relevance.

Grow NGAL commercializationLyhyt aikaväli

The core business depends on converting regulatory approvals into routine clinical use.

Broaden the biomarker pipelineKeskipitkä aikaväli

Additional kidney biomarker products can reduce dependence on a single assay family.

Strengthen international market accessKeskipitkä aikaväli

Cross-border regulatory and distribution coverage is essential for scaling a diagnostics platform.

Maantiede

BioPorto is headquartered in Denmark and operates as a regulated diagnostics business with international commercial reach. Its NGAL products are marketed under CE mark registrations in several countries worldwide and include FDA-cleared offerings, indicating activity across Europe and the United States as key markets. Geography matters because regulatory approvals, reimbursement pathways, and distributor coverage shape where the tests can be sold and adopted.

Riskit

BioPorto's main risks stem from regulatory dependence, adoption uncertainty, and concentration on a narrow diagnostic platform. As an in vitro diagnostics company, it also faces reimbursement, commercialization, and competitive risks typical of biomarker-based medical products, where clinical uptake can be slower than expected and evidence requirements are high.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Single-platform concentration1Regulatory access risk2Clinical adoption risk3Reimbursement and procurement risk4
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Single-platform concentrationVaikutus: KorkeaTodennäköisyys: Korkea

    The company is centered on NGAL and kidney biomarker products, creating product concentration risk.

    Kohdistuu: Core NGAL assay family

  2. Regulatory access riskVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Sales depend on maintaining and expanding CE mark and FDA-related approvals across markets.

    Kohdistuu: NGAL tests and other regulated diagnostics

  3. Clinical adoption riskVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    Hospitals and laboratories may adopt new biomarker tests slowly due to workflow and evidence requirements.

    Kohdistuu: AKI diagnostic commercialization

  4. Reimbursement and procurement riskVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    Even medically useful diagnostics can face slow uptake if payment and purchasing pathways are uncertain.

    Kohdistuu: International hospital and lab sales

Kysy Clarifolta: BIOPORTO A/S

Kirjanpito

Harkinnanvaraiset erät
Deferred tax asset recoverability

Management concluded the tax asset was not sufficiently probable to recognize, so future tax benefits may not appear on the balance sheet.

Vaikutus: Can materially affect equity and tax expense presentation

Divestment gain recognition

Sale of the antibody business generated a one-time gain that flows through other operating income.

Vaikutus: Can distort comparability of underlying operating performance

Share-based compensation

Warrants create equity-settled expense recognition over vesting periods.

Vaikutus: Affects personnel cost and equity

Receivables impairment

Bad debt allowances are needed where customer collection risk exists.

Vaikutus: Affects net revenue realization and working capital

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Anbio Biotechnology

NNNN · In Vitro & In Vivo Diagnostic Substances

Cryoport, Inc.

CYRX · Pharmaceutical Preparations

Bluejay Diagnostics, Inc.

BJDX · Surgical & Medical Instruments & Apparatus

bioAffinity Technologies, Inc.

BIAF · Services-Commercial Physical & Biological Research

Repligen Corporation

RGEN · Biological Products, (No Diagnostic Substances)

Bionano Genomics, Inc.

BNGO · Laboratory Analytical Instruments

Päivitetty: 24.10.2026